TMDX - Company ID 0001756262
The table below shows TransMedics Group, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $173.93M | $143.82M | $157.37M | $143.54M | $108.76M | $114.31M |
| Cost of revenue | $72.77M | $59.25M | $60.78M | $55.31M | $47.92M | $45.04M |
| Gross profit | $101.16M | $84.58M | $96.59M | $88.23M | $60.84M | $69.26M |
| R&D | $24.88M | $15.26M | $15.93M | $17.16M | $14.27M | $13.86M |
TransMedics Group, Inc. reported annual revenue of $605.49M for fiscal year 2025. That is up 37.1% from $441.54M in fiscal 2024. Over the 8 fiscal years shown, annual revenue grew from $13.02M (FY 2018) to $605.49M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A | $62.98M | $46.02M | $44.09M | $43.63M | $42.66M | $42.90M |
| Operating income | $13.30M | $23.30M | $36.57M | $27.44M | $3.92M | $12.51M |
| Income tax | $1.17M | -$1.29M | $1.27M | $994.00K | $29.00K | -$41.00K |
| Net income | $7.32M | $24.32M | $34.91M | $25.68M | $4.22M | $12.19M |
| EPS (diluted) | $0.20 | $0.66 | $0.92 | $0.70 | $0.12 | $0.35 |